Our cell based screening platform enables better decision making earlier in the drug development process, saving you precious resources and time. Equipped with the powerful Acumen eX3 platform, Crown Bioscience provides high quality cell-based assay services using high content and high throughput drug screening technology.
Currently we offer services with more than 250 cancer cell lines in:
- Cytotoxicity assays (e.g. MTS, SRB, BrdU)
- Clonogenicity assays
- Apoptosis
- Cell cycle analysis
- In vitro drug combination studies
In addition to building one of the largest cell based assay panels, Crown Bioscience has developed a panel of unique human primary cancer cell lines which better mimic original patient biology.